Back to Search Start Over

Adipophilin as prognostic biomarker in clear cell renal cell carcinoma.

Authors :
Tolkach Y
Lüders C
Meller S
Jung K
Stephan C
Kristiansen G
Source :
Oncotarget [Oncotarget] 2017 Apr 25; Vol. 8 (17), pp. 28672-28682.
Publication Year :
2017

Abstract

Objective: To study the expression of adipophilin (PLIN2), a lipid storage-associated cell protein, in different subtypes of renal cell cancer and to elucidate its prognostic value.<br />Materials and Methods: Two-hundred-seventy-five patients with renal cell carcinoma (RCC) were included in this study. Immunohistochemistry with a polyclonal antibody to adipophilin was used on the tissue microarray (formalin-fixed, paraffin-embedded tissue) for detection of adipophilin. Median follow-up time was 91 (range 1-159) months in the whole cohort and 100 (1-159) months for patients with clear-cell RCC. Additional validation for adipophilin was performed using publicly available gene expression data for clear cell RCC from The Cancer Genome Atlas (TCGA).<br />Results: Adipophilin expression was detected in 14.3% of papillary RCC, in 0% of chromophobe RCC and in 58.7% of clear-cell RCC in the cytoplasm or at the membrane. Only membrane expression was correlated with other clinical parameters (pT-stage, pN-stage, R-status, sex) and showed a prognostic significance in univariate analysis with regard to overall survival of patients with clear cell subtype (HR 2.90, 95% CI 1.55-5.42, p=0.001), which failed significance on multivariate analysis. mRNA expression of PLIN2 on TCGA data using best selected cut-off was prognostically significant in both univariate (HR 1.76, 95% CI 1.28-2.42, p = 0.0005) and multivariate analyses (HR 1.46, 95% CI 1.05-2.04, p = 0.0257).<br />Conclusions: Adipophilin is a novel and still understudied prognostic biomarker in clear cell renal cell carcinoma which deserves further study.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
17
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
28404922
Full Text :
https://doi.org/10.18632/oncotarget.15639